At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Post-Market Trading 03-18 17:37:14 EDT
39.65
+0.98
+2.53%
盘后39.65
+0.000.00%
16:05 EDT
High40.98
Low38.75
Vol516.38K
Open39.50
D1 Closing38.67
Amplitude5.78%
Mkt Cap2.51B
Tradable Cap1.12B
Total Shares63.28M
T/O20.65M
T/O Rate1.83%
Tradable Shares28.14M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
MoonLake Immunotherap Initiated at Outperform by RBC Capital
MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.